Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported
A recent SEC Form 144 filing from Arvinas, Inc. (NASDAQ: ARVN) reported the settlement of 2,197 restricted stock units (RSU) on May 21, 2026. The filing also detailed two stock sales by insider Randy Teel, involving 4,786 shares on February 23, 2026, and 9,657 shares on May 11, 2026, with gross proceeds of $58,197.76 and $95,965.47 respectively. These transactions, reported under a Form 144, reflect individual dispositions and an RSU settlement, with limited details on sales methods or prearranged plans.
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com
Arvinas Inc. reported Q1 2026 earnings with an EPS of -$0.90, surpassing the forecast, but revenue of $15.6 million fell short of expectations. The company secured FDA approval for VEPPANU, a significant milestone for its drug pipeline, and entered a global licensing agreement with Rigel Pharmaceuticals for its commercialization. Arvinas aims to focus on its phase I clinical programs and is anticipating multiple clinical updates and new trial starts throughout 2026.
Arvinas (ARVN) moves 6.9% higher: Will this strength last?
This article examines the recent 6.9% stock price increase for Arvinas (ARVN) and questions its sustainability. It will likely delve into factors contributing to this movement and potential future performance.
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)
Analysts have significantly upgraded their statutory forecasts for Arvinas, Inc. (NASDAQ:ARVN) for the current year, increasing revenue estimates to US$122m and reducing projected losses to US$2.77 per share. This indicates a substantial improvement in the company's business fundamentals and accelerated growth, with revenue expected to grow 52% annually to the end of 2026, outperforming the industry average. Despite these positive revisions, the analysts maintained their price target of US$15.00.
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Analysts have significantly upgraded their forecasts for Arvinas, Inc. (NASDAQ:ARVN), with an average price target increase of 14% to US$61. This upgrade reflects a more optimistic outlook driven by an average 18% revenue growth per year, alongside a substantial reduction in expected losses. The consensus is now a "Buy" rating, indicating strong confidence in the company's future performance.
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy
Pfizer and Arvinas have entered into a licensing agreement with Rigel Pharmaceuticals to develop and commercialize a breast cancer therapy. This collaboration aims to advance the treatment options for patients with breast cancer by combining the expertise of the three companies.
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN
Vanguard Group Inc. reduced its stake in Arvinas, Inc. (NASDAQ:ARVN) by 15.6% in the fourth quarter, selling over 1.3 million shares and retaining an 11.26% ownership worth $85.7 million. This comes after Arvinas secured a global licensing deal for VEPPANU and reported a smaller-than-expected loss per share despite missing revenue estimates. Analyst confidence in Arvinas has been boosted, with BTIG Research raising its price target to $18 and reiterating a buy rating.
Arvinas CSO Angela Cacace sells $95,965 in company stock
Arvinas Chief Scientific Officer Angela M. Cacace sold 9,657 shares of the company's common stock for approximately $95,965. This sale was not discretionary but an automatic execution to cover tax obligations related to vested restricted stock units. Following the transaction, Ms. Cacace directly owns 182,966 shares of Arvinas common stock.
Arvinas (ARVN) VP Loomis has 1,919 shares sold to cover RSU taxes
Arvinas (ARVN) VP and Chief Accounting Officer, David K. Loomis, sold 1,919 shares of common stock on May 11, 2026, at $9.9374 per share. This transaction was an automatic sale by the company to cover tax withholding obligations on vested Restricted Stock Units (RSUs) and was not a discretionary trade. After the sale, Loomis directly holds 40,193 shares of Arvinas common stock.
Arvinas (ARVN) CSO share sale covers RSU tax withholding
Arvinas, Inc.'s Chief Scientific Officer, Angela M. Cacace, automatically sold 9,657 shares of common stock at $9.9374 per share on May 11, 2026. This transaction was not a discretionary trade but rather executed by the company to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted on May 9, 2025. Following the sale, Ms. Cacace directly owns 182,966 shares of Arvinas common stock.
Arvinas president and CEO Randy Teel sells $95,965 in stock
Arvinas President and CEO Randy Teel sold 9,657 shares of the company's common stock for $95,965 on May 11, 2026. This transaction was not a discretionary sale but was automatically executed to cover tax withholding obligations related to the vesting of restricted stock units. Following the sale, Mr. Teel directly owns 287,218 shares of Arvinas stock.
Arvinas anticipates US ARV-102 PSP trial by end of 2026 while maintaining cash runway into second half of 2028
Arvinas expects to initiate a U.S. trial for its drug candidate ARV-102 for patients with progressive supranuclear palsy (PSP) by the end of 2026. The company also projects its current cash reserves will fund operations into the second half of 2028, indicating a stable financial outlook for its ongoing research and development efforts.
Arvinas (NASDAQ: ARVN) gains first PROTAC FDA nod as Q1 2026 swings to loss
Arvinas reported a significant milestone with FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader, for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. Despite this approval, the company experienced a sharp revenue decline to $15.6 million from $188.8 million in the prior year and swung to a net loss of $57.6 million in Q1 2026. Arvinas maintains a strong cash position of $614.9 million, projected to fund operations into the second half of 2028, and continues to advance a broad PROTAC pipeline.
Will Arvinas (NASDAQ:ARVN) Spend Its Cash Wisely?
Arvinas (NASDAQ: ARVN), a biotechnology company, has a cash runway of 2.5 years based on its December 2025 cash balance of US$685 million and an annual cash burn of US$276 million. While the company's cash runway is decent, its cash burn of 42% of its market capitalization (US$652 million) suggests that raising additional capital in the future could be significantly dilutive for shareholders. The article advises shareholders to consider the potential cost of future capital raising, despite the reassuring current cash runway.
ARVINAS, INC. 1Q 2026: Revenue $15.6M, Net income ($57.6M), EPS ($0.9) — 10-Q Summary
ARVINAS, INC. reported a significant year-over-year decline in its first-quarter 2026 financial results, with revenue falling to $15.6 million and a net loss of $57.6 million. Despite the financial downturn, the company achieved FDA approval for VEPPANU™, advanced several clinical programs, and implemented cost-reduction measures and program prioritization to extend its cash runway into the second half of 2028.
(ARVN) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Arvinas Inc. (NASDAQ: ARVN), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes elevated downside risk and the need for sophisticated risk management.
Brummer Multi Strategy AB Makes New $1.97 Million Investment in Arvinas, Inc. $ARVN
Brummer Multi Strategy AB has made a new $1.97 million investment in Arvinas, Inc. (NASDAQ:ARVN), acquiring 166,342 shares in the fourth quarter, making it their third-largest holding. Despite significant insider selling totaling $802,443 over the last 90 days, institutional investors collectively own 95.19% of the stock. Arvinas reported a weak financial quarter with a larger-than-expected loss and lower revenue, leading to a mixed outlook from analysts with an average target price of $14.86.
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of "Hold" from Brokerages
Arvinas, Inc. (NASDAQ:ARVN) has received a consensus "Hold" rating from fifteen brokerages, with an average 12-month price target of $14.86. Recent analyst actions have been mixed, and the company reported a weak quarter with a larger-than-expected loss and lower revenue. Insider selling by the CFO and CEO has also been noted.
[144] ARVINAS, INC. SEC Filing
Arvinas, Inc. (NASDAQ: ARVN) has filed a Form 144 notice regarding the proposed sale of 11,343 RSU shares, with the settlement scheduled for May 11, 2026, handled by Morgan Stanley Smith Barney LLC. The filing also disclosed a prior sale of 5,134 shares by Andrew Saik on February 13, 2026, for $61,043.26. This SEC filing provides details on the securities to be sold, key figures, and definitions of relevant terms like restricted stock units and Form 144.
ARVN SEC Filings - Arvinas 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Arvinas (ARVN) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms. It details recent insider trading activities, such as equity grants to a board member and tax-related stock sales by the CFO and Chief Scientific Officer, along with summaries and impact analyses. The resource aims to help investors understand Arvinas's regulatory disclosures and corporate developments.
Arvinas Inc expected to post a loss of 92 cents a share - Earnings Preview
Arvinas Inc is anticipated to report a loss of 92 cents per share, according to this earnings preview. The article, sourced from Refinitiv, gives no further details on the company's financial outlook or upcoming earnings call. This brief report suggests a negative financial forecast for Arvinas Inc.
[144] ARVINAS, INC. SEC Filing
Arvinas, Inc. has filed a Form 144 with the SEC, indicating a proposed sale of 9,834 shares related to the settlement of vested restricted stock units on May 11, 2026. The filing also details two prior dispositions by Angela Cacace on February 13, 2026, and February 23, 2026, for 4,592 and 3,609 shares respectively, with corresponding proceeds. The broker for the proposed sale is Morgan Stanley Smith Barney LLC.
What Arvinas says on May 12: Q1 results and corporate update
Arvinas (Nasdaq: ARVN) will report its first quarter 2026 financial results and provide a corporate update during a live webcast on May 12, 2026, at 8:00 a.m. ET. The webcast will be accessible through the company's investor website, with a replay available afterward. This event follows recent company news, including FDA approval for VEPPANU and positive ARV-102 data.
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas, Inc. announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:00 a.m. ET. The event will be a live webcast accessible through the "Events and Presentations" section of the company's investor page. A replay will also be available on the Arvinas website following the webcast.
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
Pfizer and Arvinas Inc. received FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind PROTAC therapy for advanced breast cancer. The approval, ahead of schedule, covers estrogen receptor-positive (ER+)/HER2-negative, ESR1-mutated advanced or metastatic breast cancer, based on positive Phase 3 trial data showing improved progression-free survival. Guardant Health's Guardant360 CDx liquid biopsy test was also approved as a companion diagnostic to identify eligible patients.
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Guardant Health's Guardant360® CDx liquid biopsy test has received FDA approval as a companion diagnostic for VEPPANU (vepdegestrant), a treatment developed by Arvinas and Pfizer. This approval allows for the identification of patients with ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations who may benefit from VEPPANU. This marks Guardant's third FDA approval for an ESR1 companion diagnostic, furthering personalized treatment options for breast cancer.
Protein degraders gain speed as Arvinas scores landmark approval
Arvinas has received FDA approval for vepdegestrant, a first-of-its-kind PROTAC protein degrader for breast cancer, marking a significant milestone for this drug class. Despite narrower-than-expected clinical benefits and a reshaped strategy for Arvinas, the protein degrader field is gaining momentum with other companies like Novartis and Bristol Myers Squibb making substantial investments. Arvinas is now shifting its focus to earlier-stage programs, including neurodegeneration and oncology, to leverage the broader potential of targeted protein degradation.
Arvinas/Pfizer To Announce Veppanu Commercialization Partner In Weeks
Arvinas and Pfizer are expected to announce a commercialization partner for their recently FDA-approved drug, Veppanu (vepdegestrant), within weeks. The article highlights this development as significant news in the biopharma industry. No further details about potential partners or commercialization strategies are provided.
Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN
Hussman Strategic Advisors Inc. initiated a new position in Arvinas, Inc. (NASDAQ:ARVN) during the fourth quarter, purchasing 105,000 shares valued at approximately $1.245 million. Institutional investors collectively hold about 95.19% of the company's stock, despite the company missing earnings expectations and experiencing significant revenue decline in its latest quarter. Analysts currently maintain a "Hold" rating on Arvinas, with a consensus price target of $14.13, while insider selling has also been noted.
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
The FDA has approved Arvinas and Pfizer's Veppanu, a PROTAC drug, for treating certain ER-positive, HER2-negative metastatic breast cancer patients with ESR1 mutations whose disease has progressed. This marks the first approved protein-degrading medicine of its kind. Despite the approval, Arvinas and Pfizer are still seeking a partner to commercialize Veppanu due to investor skepticism regarding its commercial potential compared to other oral hormone-degrading drugs on the market, leading Arvinas to refocus on other PROTACs in its pipeline.
FDA approves first PROTAC drug for ESR1-mutated breast cancer
Arvinas (Nasdaq: ARVN) announced FDA approval for VEPPANU (vepdegestrant) for adults with ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer, making it the first FDA-approved PROTAC therapy. The approval was based on data from the VERITAC-2 trial, which showed a significant 43% reduction in the risk of disease progression or death compared to fulvestrant, with a median progression-free survival of 5 months for VEPPANU. This milestone addresses a critical unmet need for patients who have progressed on endocrine therapy and resulted in a positive market reaction for ARVN stock.
Arvinas shares gain as FDA approves breast cancer drug Veppanu By Investing.com
Arvinas Inc. shares surged by as much as 13% following the FDA's approval of its breast cancer drug, VEPPANU. This drug treats estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after previous endocrine therapy. Notably, VEPPANU is the first FDA-approved PROTAC (heterobifunctional protein degrader therapy), and its approval came earlier than the anticipated PDUFA date.
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant)
Arvinas, Inc., in partnership with Pfizer Inc., has received FDA approval for VEPPANU (vepdegestrant) to treat advanced or metastatic ER+/HER2-, ESR1-mutated breast cancer, marking the first FDA-approved PROteolysis TArgeting Chimera (PROTAC) therapy. The approval was granted ahead of schedule, based on significant improvements in progression-free survival shown in the VERITAC-2 clinical trial. This new oral treatment addresses a critical unmet need for patients who have progressed after endocrine therapy.
(ARVN) Movement as an Input in Quant Signal Sets
This article analyzes Arvinas Inc. (NASDAQ: ARVN)'s stock movement using quantitative signals, highlighting weak near and mid-term sentiment but a strong long-term outlook. It provides AI-generated trading strategies including long, short, and momentum breakout options, along with multi-timeframe signal analysis for support and resistance levels. The analysis indicates elevated downside risk due to the absence of additional long-term support signals.
[ARS] ARVINAS, INC. SEC Filing
This article announces an SEC filing for ARVINAS, INC. (ARVN) on April 29, 2026, classified as an ARS type. It provides details on the filing's low impact and neutral sentiment, along with links to the full PDF document and the original SEC EDGAR source. The page also includes an overview of ARVN's stock data, recent news, and other SEC filings.
Arvinas (NASDAQ: ARVN) details 2026 virtual meeting, director and pay votes
Arvinas (NASDAQ: ARVN) has detailed the agenda for its 2026 Annual Meeting of Stockholders, which will be held virtually on June 24, 2026. Stockholders will vote on the election of two Class II directors, an advisory resolution on executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. The company has also provided extensive information on executive and director compensation, including base salaries, cash bonuses, long-term equity incentives, and severance provisions, emphasizing a pay-for-performance philosophy and stockholder engagement.
Arvinas (NASDAQ:ARVN) Downgraded to "Strong Sell" Rating by Zacks Research
Zacks Research has downgraded Arvinas (NASDAQ:ARVN) to a "strong sell" rating. This follows various analyst ratings including "sell" from Weiss Ratings and Wall Street Zen, despite some "buy" ratings and increased price targets from others. The company recently missed its quarterly earnings estimates and experienced significant insider selling, balanced by some insider buying.
Vanguard Portfolio Management owns 3.92M Arvinas shares (ARVN)
Vanguard Portfolio Management has reported beneficial ownership of 3,917,671 shares of Arvinas Inc. (ARVN), representing 6.12% of the company's common stock. This disclosure was made via a Schedule 13G SEC filing, confirming Vanguard's sole dispositive power over these shares and sole voting power for 28,043 shares. The filing, signed by Ashley Grim on April 28, 2026, indicates the ownership amount as of March 31, 2026.
Arvinas CEO John Houston to retire
John Houston, CEO of Arvinas, is set to retire. The article from MSN provides no further details regarding the date, reason for retirement, or implications for the company.
Arvinas announces $100M share repurchase program
Arvinas, Inc. (ARVN) announced that its Board of Directors has authorized a share repurchase program, allowing the company to buy back up to $100 million of its common stock. The program has no expiration date and will be executed through open market purchases or privately negotiated transactions.
Arvinas announces $100M share repurchase program
Arvinas, Inc. has announced a share repurchase program authorizing the company to buy back up to $100 million of its common stock. The program has no fixed expiration date and will be executed through open market purchases or other transactions. Future repurchases depend on various factors including market conditions and stock price.
Arvinas stock slides after eliminating trials, reducing workforce
Arvinas (ARVN) stock fell significantly after the company announced it would discontinue two clinical trials and reduce its workforce by approximately 17%. These decisions are part of a strategic reprioritization to focus on its most promising assets, particularly the protein degrader vepdegestrant and its neurology portfolio. The restructuring is expected to extend the company's cash runway into 2027.
Arvinas (ARVN) Expected to Announce Earnings on Thursday
Arvinas (ARVN) is set to release its Q1 2026 earnings before market open on Thursday, April 30th, with analysts forecasting an EPS of ($0.94) and revenue of $17.164 million. The company significantly missed prior quarter estimates, and revenue declined 84% year-over-year. Despite a "Hold" consensus rating and an average price target of $13.88, insiders have been net sellers, while institutional investors hold over 95% of the stock.
Arvinas unveils preclinical findings for HPK1 and pan-KRAS PROTAC candidates
Arvinas is presenting preclinical data for its HPK1 degrader and pan-KRAS degrader PROTAC candidates at the AACR Annual Meeting. These early-stage oncology innovations aim to disrupt critical signaling pathways for cancer treatment. The company seeks to highlight advancements in targeted protein degradation therapies through these findings.
JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN
JPMorgan Chase & Co. significantly increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 475.5% in Q3, now holding 214,779 shares valued at $1.83 million. Despite substantial institutional investment, Arvinas reported a weak quarter with an 84% revenue plunge and missed EPS expectations, leading to a "Hold" consensus among analysts with a $13.88 average price target. Insider activity shows both buying from a director and recent selling, reflecting mixed sentiment around the biopharmaceutical company focused on targeted protein degradation.
ARVN Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Arvinas Inc (ARVN), indicating a "Sell" consensus based on various indicators. It details the company's moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels. The analysis highlights that while some individual moving averages show "Buy" signals, the overall technical sentiment points towards a "Sell" for ARVN.
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) shares jumped 6.9% following positive investor expectations for its pipeline, specifically encouraging data from an early-stage study of ARV-102 for Parkinson's disease. Despite this, the company faces negative earnings estimate revisions for the upcoming quarter, with expected losses and a significant drop in revenue. The stock currently holds a Zacks Rank #3 (Hold), prompting a watchful eye on whether its recent gain can be sustained.
Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Time to Sell?
Arvinas (NASDAQ:ARVN) shares dropped 5.1% after reporting a significant earnings and revenue miss for Q4, with EPS at ($1.10) against an estimated ($0.55) and revenue of $9.5M versus $37.26M consensus. Despite analyst price target increases and several "Buy" ratings, the stock holds a mixed "Hold" consensus due to the substantial revenue decline. Insider selling and institutional ownership percentages are also detailed.
Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained?
Shares of Arvinas, Inc. (ARVN) recently surged 6.9% due to investor optimism over promising early-phase trial results for ARV-102, a Parkinsons' disease treatment candidate. Despite this positive momentum, the company faces projected quarterly losses and a significant decline in revenue expectations, and its consensus EPS estimates have been lowered. The stock currently holds a Zacks Rank #3 (Hold).
Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained?
Shares of Arvinas, Inc. (ARVN) recently surged 6.9% due to investor optimism following positive early-phase trial results for ARV-102, a Parkinson's disease treatment candidate. Despite the recent stock increase, the company faces a projected quarterly loss and a significant revenue drop year-over-year, alongside recent downward revisions in EPS estimates. Investors are advised to monitor the stock, which currently holds a Zacks Rank #3 (Hold).
